Silence Therapeutics plc is a clinical-stage biotechnology company that discovers and develops novel short interfering ribonucleic acid (siRNA) therapeutics. Headquartered in London, the company utilizes its proprietary mRNAi GOLD platform to precisely target and silence disease-associated genes in the liver. Its clinical pipeline focuses on addressing high unmet medical needs in cardiovascular disease, hematology, and rare diseases. Key product candidates include divesiran for the treatment of polycythemia vera and zerlasiran for cardiovascular disease associated with elevated lipoprotein(a). The company also engages in strategic partnerships with major pharmaceutical firms, such as AstraZeneca and Hansoh Pharma, to co-develop and commercialize its precision-engineered medicines globally.
